Research programme : anti-Ras antibody therapeutics - Ajou University/Orum Therapeutics
Alternative Names: RT 11iLatest Information Update: 28 Jun 2021
At a glance
- Originator Ajou University School of Medicine; Orum Therapeutics
- Developer Ajou University School of Medicine
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 10 May 2017 Research programme : anti-Ras antibody therapeutics - Ajou University/Orum Therapeutics is available for licensing as of 10 May 2017. http://www.orumrx.com/
- 10 May 2017 Preclinical trials in Cancer in South Korea (Parenteral)